Ignite Creation Date:
2025-12-24 @ 9:07 PM
Ignite Modification Date:
2026-01-01 @ 2:53 PM
Study NCT ID:
NCT03029104
Status:
TERMINATED
Last Update Posted:
2022-01-12
First Post:
2017-01-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas
Sponsor:
Cxlusa
Organization:
Study Overview
Official Title:
Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas
Status:
TERMINATED
Status Verified Date:
2021-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sufficient clinical results obtained to support study endpoints.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess changes in visual acuity and corneal symmetry after corneal collagen cross-linking (CXL) of asymmetric corneas.
Detailed Description:
This study will evaluate the results of Corneal Collagen Crosslinking (CXL) in patients with conditions that include keratoconus, forme fruste keratoconus, post-LASIK ectasia, pellucid marginal degeneration, forme fruste pellucid marginal degeneration, diurnal fluctuation post-radial keratotomy, or Terrien's marginal degeneration. This is an outcomes study, all patients receive treatment.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
True
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: